Importo totale (1 articolo articoli):
Destinazione ordine:
öner tulum (45 risultati)
Vai alla pagina principale dei risultati di ricerca
Filtri di ricerca
Tipo di articolo
- Tutti i tipi di prodotto
- Libri (45)
- Riviste e Giornali (Nessun altro risultato corrispondente a questo perfezionamento)
- Fumetti (Nessun altro risultato corrispondente a questo perfezionamento)
- Spartiti (Nessun altro risultato corrispondente a questo perfezionamento)
- Arte, Stampe e Poster (Nessun altro risultato corrispondente a questo perfezionamento)
- Fotografie (Nessun altro risultato corrispondente a questo perfezionamento)
- Mappe (Nessun altro risultato corrispondente a questo perfezionamento)
- Manoscritti e Collezionismo cartaceo (Nessun altro risultato corrispondente a questo perfezionamento)
Condizioni Maggiori informazioni
- Nuovo (39)
- Come nuovo, Ottimo o Quasi ottimo (6)
- Molto buono o Buono (Nessun altro risultato corrispondente a questo perfezionamento)
- Discreto o Mediocre (Nessun altro risultato corrispondente a questo perfezionamento)
- Come descritto (Nessun altro risultato corrispondente a questo perfezionamento)
Legatura
Ulteriori caratteristiche
- Prima ed. (Nessun altro risultato corrispondente a questo perfezionamento)
- Copia autograf. (Nessun altro risultato corrispondente a questo perfezionamento)
- Sovracoperta (Nessun altro risultato corrispondente a questo perfezionamento)
- Con foto (15)
- Non Print on Demand (33)
Lingua (1)
Spedizione gratuita
Paese del venditore
Valutazione venditore
-
From Financialisation to Innovation in UK Big Pharma
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, GB, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: Rarewaves.com USA, London, LONDO, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 24,27
Spedizione gratuita
Spedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: New. The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to 'downsize-and-distribute'. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: GreatBookPrices, Columbia, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 21,94
Spedizione EUR 2,27
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: GreatBookPrices, Columbia, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 24,51
Spedizione EUR 2,27
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
Innovation versus Financialization in the US Pharmaceutical Industry (Elements in Corporate Governance)
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: California Books, Miami, FL, U.S.A.
Valutazione del venditore 4 su 5 stelle
EUR 27,47
Spedizione gratuita
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
From Financialisation to Innovation in UK Big Pharma (Elements in Reinventing Capitalism)
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: California Books, Miami, FL, U.S.A.
Valutazione del venditore 4 su 5 stelle
EUR 27,47
Spedizione gratuita
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: GreatBookPrices, Columbia, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 25,33
Spedizione EUR 2,27
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: Rarewaves.com USA, London, LONDO, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 28,12
Spedizione gratuita
Spedito da Regno Unito a U.S.A.Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
EUR 29,58
Spedizione gratuita
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloPaperback. Condizione: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: GreatBookPrices, Columbia, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 27,35
Spedizione EUR 2,27
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
-
From Financialisation to Innovation in UK Big Pharma (Elements in Reinventing Capitalism)
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: Ria Christie Collections, Uxbridge, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 21,41
Spedizione EUR 13,74
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
-
From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: Kennys Bookstore, Olney, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
Condizione: New. 2022. Paperback. . . . . . Books ship from the US and Ireland.
-
From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 24,06
Spedizione EUR 14,50
Spedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Aggiungi al carrelloPaperback / softback. Condizione: New. New copy - Usually dispatched within 3 working days.
-
Innovation Versus Financialization in the Us Pharmaceutical Industry (Elements in Corporate Governance)
Lingua: Inglese
Editore: Cambridge University Press -, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: Chiron Media, Wallingford, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 21,80
Spedizione EUR 17,76
Spedito da Regno Unito a U.S.A.Quantità: 3 disponibili
Aggiungi al carrellopaperback. Condizione: New.
-
From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline (Elements in Reinventing Capitalism)
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: Books Puddle, New York, NY, U.S.A.
Valutazione del venditore 4 su 5 stelle
Condizione: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 24,73
Spedizione EUR 17,20
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 25,55
Spedizione EUR 17,20
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: Revaluation Books, Exeter, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 32,90
Spedizione EUR 11,47
Spedito da Regno Unito a U.S.A.Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 96 pages. 6.00x0.22x9.00 inches. In Stock.
-
Innovation versus Financialization in the US Pharmaceutical Industry (Elements in Corporate Governance)
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: Kennys Bookstore, Olney, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
Condizione: New. 2025. paperback. . . . . . Books ship from the US and Ireland.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 29,15
Spedizione EUR 17,20
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 29,14
Spedizione EUR 17,20
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry (Paperback)
Lingua: Inglese
Editore: Cambridge University Press, Cambridge, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: CitiRetail, Stevenage, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 27,74
Spedizione EUR 42,43
Spedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: new. Paperback. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research. The US government is negotiating with pharmaceutical companies on the price of ten drugs. This Element shows that the companies (a) should have their drug prices regulated, (b) use their profits to distribute cash dividends and stock buybacks; (c) do not rely on investment by shareholders; and (d) benefit from 'collective and cumulative learning.' Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: Rarewaves USA United, OSWEGO, IL, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 31,12
Spedizione EUR 43,02
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloPaperback. Condizione: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
From Financialisation to Innovation in UK Big Pharma: Astrazeneca and Glaxosmithkline
Libro 4 di 8: Elements in Reinventing CapitalismEUR 25,14
Spedizione EUR 48,99
Spedito da Germania a U.S.A.Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New. Inhaltsverzeichnis1. Introduction 2. Innovation and Competition in the Global Pharmaceutical Industry 3. The Innovation-Financialisation Tension in the Global Pharmaceutical Industry 4. AstraZeneca 5. GlaxoSmithKline 6. Explaining t.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Da: GreatBookPrices, Columbia, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 77,91
Spedizione EUR 2,27
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Da: GreatBookPrices, Columbia, MD, U.S.A.
Valutazione del venditore 5 su 5 stelle
EUR 82,98
Spedizione EUR 2,27
Spedito in U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
EUR 27,79
Spedizione EUR 60,77
Spedito da Germania a U.S.A.Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
From Financialisation to Innovation in UK Big Pharma
Libro 4 di 8: Elements in Reinventing CapitalismLingua: Inglese
Editore: Cambridge University Press, GB, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Da: Rarewaves.com UK, London, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 21,18
Spedizione EUR 74,53
Spedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: New. The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to 'downsize-and-distribute'. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 78,51
Spedizione EUR 17,20
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 79,13
Spedizione EUR 17,20
Spedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Lingua: Inglese
Editore: Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Da: Rarewaves.com UK, London, Regno Unito
Valutazione del venditore 5 su 5 stelle
EUR 25,21
Spedizione EUR 74,53
Spedito da Regno Unito a U.S.A.Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
